Capital Research Global Investors’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-420,868
Closed -$87.6M 447
2022
Q4
$87.6M Hold
420,868
0.03% 287
2022
Q3
$91.9M Sell
420,868
-103,604
-20% -$23.6M 0.03% 271
2022
Q2
$110M Sell
524,472
-33,086
-6% -$7.04M 0.03% 265
2022
Q1
$135M Buy
557,558
+253,121
+83% +$61.2M 0.03% 282
2021
Q4
$79.3M Buy
+304,437
New +$79M 0.02% 339
2016
Q2
Sell
-260,000
Closed -$15M 432
2016
Q1
$15M Sell
260,000
-8,519,255
-97% -$482M 0.01% 390
2015
Q4
$471M Sell
8,779,255
-2,016,745
-19% -$114M 0.16% 141
2015
Q3
$550M Sell
10,796,000
-609,500
-5% -$32.8M 0.2% 124
2015
Q2
$643M Buy
11,405,500
+1,814,300
+19% +$115M 0.21% 111
2015
Q1
$688M Hold
9,591,200
0.24% 108
2014
Q4
$538M Buy
9,591,200
+2,893,200
+43% +$151M 0.18% 129
2014
Q3
$330M Buy
6,698,000
+650,000
+11% +$33.1M 0.11% 177
2014
Q2
$306M Buy
6,048,000
+54,000
+0.9% +$2.68M 0.11% 180
2014
Q1
$268M Sell
5,994,000
-2,250,000
-27% -$101M 0.1% 192
2013
Q4
$388M Buy
8,244,000
+554,000
+7% +$28M 0.14% 150
2013
Q3
$406M Buy
7,690,000
+382,449
+5% +$18.6M 0.16% 145
2013
Q2
$330M Buy
+7,307,551
New +$347M 0.14% 152

Other funds holding RMD

Capital Research Global Investors's RMD Position: Q1 2023 in Review

Capital Research Global Investors sold out of ResMed (RMD) in Q1 2023, closing a stake of 420,868 shares — an estimated $87.6M sold.

Capital Research Global Investors first reported a position in RMD in Q2 2013 and held it in 17 quarters. The position peaked at $688M in Q1 2015. 677 funds tracked by Wall St. Rank hold RMD as of Q1 2023.

  • Capital Research Global Investors reported no remaining ResMed position as of Q1 2023 after selling out during the quarter.
  • Capital Research Global Investors sold 420,868 ResMed shares in Q1 2023, an estimated $87.6M.
  • Capital Research Global Investors first reported a position in ResMed in Q2 2013 and held it in 17 quarters.
  • Capital Research Global Investors's ResMed position peaked at $688M in Q1 2015.
  • 677 funds tracked by Wall St. Rank held ResMed as of Q1 2023.

Based on Capital Research Global Investors's 13F filing for Q1 2023, filed 15 May 2023.